NewAmsterdam Pharma (NAMS) EPS (Weighted Average and Diluted) (2023 - 2025)
Historic EPS (Weighted Average and Diluted) for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to -$0.61.
- NewAmsterdam Pharma's EPS (Weighted Average and Diluted) fell 23888.89% to -$0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.05, marking a year-over-year increase of 888.89%. This contributed to the annual value of -$2.56 for FY2024, which is 1906.98% down from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma's EPS (Weighted Average and Diluted) is -$0.61, which was down 23888.89% from -$0.15 recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's EPS (Weighted Average and Diluted) registered a high of -$0.15 during Q2 2025, and its lowest value of -$1.06 during Q1 2024.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$0.53, with a median of -$0.51 in 2023.
- Per our database at Business Quant, NewAmsterdam Pharma's EPS (Weighted Average and Diluted) skyrocketed by 6842.11% in 2024 and then plummeted by 23888.89% in 2025.
- Over the past 3 years, NewAmsterdam Pharma's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.6 in 2023, then plummeted by 58.33% to -$0.95 in 2024, then surged by 35.79% to -$0.61 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.61 for Q3 2025, versus -$0.15 for Q2 2025 and -$0.34 for Q1 2025.